Joint Annual Meeting 2014 PROGRAM

Transkript

1 PROGRAM aarau info Sarah Keller Joint Annual Meeting 2014 Swiss Society for Infectious Diseases SSI Swiss Society for Hospital Hygiene SSHH Swiss Specialists for Tropical and Travel Medicine FMH August 2014 Kultur & Kongresshaus Aarau

2 In today s HIV landscape we expect to keep them there, with durable suppression, well-established tolerability and convenient dosing. 1-5 So they can concentrate on dealing with the challenges of life. 1. Daar ES et al. Atazanavir plus ritonavir or Efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med. 2011;154: Molina JM et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviralnaïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53: Uy J et al. Treatment of advanced HIV disease in antiretroviralnaive HIV-1-infected patients receiving once-daily atazanavir/ ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. AIDS Care 2011, Nov;23(11): Bedimo R. et al. Osteoporotic risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012,26: D Arminio Montforte A. et al. Atazanavir-containing ART Is Not Associated with an Increased Risk of Cardio-or Cerebrovascular Events. AIDS 2013,27: Gekürzte Fachinformation: REYATAZ (Atazanavir, ATV) I: Reyataz ist indiziert in Kombination mit anderen antiretroviralen Substanzen für die Behandlung von HIV-1 infizierten Erwachsenen oder pädiatrischen Patienten (6 Jahre bis < 18 Jahre) mit oder ohne antiretroviraler Vorbehandlung. Die Auswahl von Reyataz bei antiretroviral vorbehandelten Patienten sollte aufgrund individueller viraler Resistenztes-t ung und der Vorbehandlungsgeschichte des Patienten erfolgen. D: Die empfohlene Dosierung für Reyataz ist 300 mg 1 x täglich kombiniert mit 100 mg Ritonavir 1 x täglich zusammen mit einer Mahlzeit. Die Dosierung von Reyataz Kapseln für pädiatrische Patienten basiert auf dem Körpergewicht (siehe Tabelle FI), wobei die empfohlene Dosis für Erwachsene nicht überschritten werden sollte. Reyataz kann zusammen mit Ritonavir bei leichtgradiger Leberinsuffizienz in der Standarddosierung mit Vorsicht und unter Kontrolle der Leberparameter angewendet werden. Bei Patienten mit eingeschränkter Nierenfunktion ist keine Dosisanpassung erforderlich. KI: Überempfindlichkeit auf den Wirkstoff oder einen Hilfsstoff. Die Kombination von Reyataz/ Ritonavir mit den folgenden Arzneimitteln ist kontraindiziert: Alfuzosin, Rifampicin, Johanniskraut-Präparate, Midazolam, Triazolam, Ergotaminderivate, Amiodaron, Flecainid, Propafenon, Diltiazem, Verapamil, Simvastatin, Atorvastatin, Vardenafil, Sildenafil zur Behandlung der pulmonalen artiellen Hypertonie. Bei Patienten mit mässig bis schwer eingeschränkter Leberfunktion (Child-Pugh B und C) ist Atazanavir kontraindiziert. VM: Eine antiretrovirale Kombinationstherapie kann zu Lipodystrophie und metabolischen Störungen führen. Eine dosisabhängige, asymptomatische Verlängerung des PR-Intervalls wurde beobachtet, weshalb bei bestehenden Reizleitungsstörungen Atazanavir nur unter vorsichtiger Beobachtung angewendet werden sollte. SS: Die Anwendung von Atazanavir während der Schwangerschaft kann in Erwägung gezogen werden, wenn der zu erwartende Nutzen das potenzielle Risiko übersteigt; dabei soll die Patientin entsprechend überwacht werden. IA: Atazanavir wird in der Leber überwiegend durch das Isoenzym CYP3A4 metabolisiert. Wir bitten um Beachtung der ausführlichen Beschreibung in der Fachinformation. UAW: Sehr häufig: Nausea, Ikterus und Diarrhoea. Laborparameter: Erhöhungen des indirekten Bilirubins, Kreatinkinase, ALT/ AST, Lipase. Wir bitten um Beachtung der in der Fachinformation detailliert aufgeführten unerwünschten Wirkungen. Bei pädiatrischen Patienten: asymptomatische PR-Intervallverlängerung, asymptomatischer AV-Block Grad 1 oder 2. Packungen: Reyataz Hartgelatinekap-seln 150 mg* und 200 mg*, je zu 60 Kapseln; 300 mg*, zu 30 Kapseln. *Kassenzulässig, Abgabekategorie: A. Die vollständige Fachinformation finden Sie unter: Literatur auf Anfrage erhältlich bei: Bristol-Myers Squibb SA, Neuhofstrasse 6, 6341 Baar. 687CH14PR

3 Content Welcome to Aarau 4 General information 5-9 Organizational information 5-6 Abstract presentations and awards 7 Accommodation 8 Social evening 8 Travel information 9 Partner companies 10 Scientific program Thursday August 28, Friday August 29, Invited speakers and chairs Posters List of exhibitors 36 Exhibition plan 37 Meetings 38 Online registration:

4 Welcome Welcome to Aarau Dear colleagues, After a stimulating and successful meeting in 2013, the Swiss Societies for Infectious Diseases SSI, Hospital Hygiene SSHH and Tropical and Travel Medicine FMH decided to organize a Joint Annual Meeting again in This year's meeting will be held in Aarau from August 28 to 29, 2014 and we are pleased to announce a multifaceted program with interdisciplinary subjects which will be presented by several national and international highly qualified speakers. Beside the interdisciplinary main topics such as Hepatitis C, Antibiotic Treatment, HIV, the program is composed of free communications, posterflashes, presentations and workshops. The program also includes a "meet the expert" breakfast session and a repeat of the diagnostic quiz which was greatly appreciated in We are looking forward to another successful and inspiring congress and to welcoming you to Aarau in August 2014! For the scientific committee Prof. Ursula Flückiger, MD Congress President, Aarau Prof. Bernard Hirschel, MD President SSI, Geneva Matthias Schlegel, MD President SSHH, St.Gallen Prof. Christoph Hatz, MD President SSTTM, Basel 4

5 Organizational information Date Thursday to Friday, August 28-29, 2014 Venue Congress website Kultur & Kongresshaus Aarau Schlossplatz 9 CH-5000 Aarau General Presidents Scientific committee Congress President SSI Prof. Ursula Flückiger, MD; Aarau SSI Prof. Bernard Hirschel, MD; Geneva SSHH Matthias Schlegel, MD; St.Gallen SSTTM Prof. Christoph Hatz, MD; Basel SSI Pierre-Yves Bochud, MD; Lausanne Prof. Ursula Flückiger, MD; Aarau Christoph A. Fux, MD; Aarau Prof. Bernard Hirschel, MD; Geneva Nicolas Müller, MD; Zurich Andri Rauch, MD; Bern Claude Scheidegger, MD; Basel Andreas F. Widmer, MD; Basel SSHH Marie-Theres Meier, MD; Zurich Matthias Schlegel, MD; St.Gallen Laurence Senn, MD; Lausanne Websites of the societies Congress secretariat Registration SSTTM Pietro Antonini, MD; Lugano Prof. Christoph Hatz, MD; Basel IMK Institute for medicine and communication Ltd Münsterberg 1, CH-4001 Basel Tel: Fax: congress@imk.ch Online via 5

6 Organizational information General Registration fees (in CHF) Early bird until June 30 Regular from July 1 to August 26 Onsite Member physicians Non member physicians Assistants, nurses, PhD, post docs Students Social evening physicians 100. Social evening assistants, nurses, students 50. Cancellation policy Opening hours congress secretariat Credits Language Translation Technical information for speakers All cancellations must be faxed or electronically mailed to the congress secretariat. Cancellations received up to June 30, 2014: 50% refund will be made Cancellations received after June 30, 2014: no refund will be made Thursday, August 28, 2014, 09:30-18:00 h Friday, August 29, 2014, 07:30-16:00 h Swiss Society for Infectious Diseases: 16 Credits Specialist Society for Tropical and Travel Medicine FMH: 12 Credits Swiss Society of General Internal Medicine: 11.5 Credits The official congress language is English. Presentations in the main topics have to be in English. Workshops, Posters, Posterflashes and Free Communications may be presented in English, German or French. SSHH presentations may be in German or French. Slides for all presentations have to be in English. There will be a simultaneous translation for the opening session (English-French English-German) as well as for the SSHH sessions and the SSHH general assembly (German-French French-German). The lecture halls are equipped with a beamer and a computer. We ask the speakers to save their presentation on a USB memory drive and deliver it to the organizers in the conference room at latest in the break before the session. 6

7 Abstract presentations and awards Posterflashes Thursday, August 28, 2014, 16:00-17:00 h, Room 2. The authors are requested to prepare a short PowerPoint presentation of 5 minutes including discussion (only 2-3 slides). Free Communications Friday, August 29, 2014, 13:45-15:15 h, Room 2. The presentations within the free communication-session will be 15 minutes (including discussion). The authors are requested to prepare a PowerPoint presentation. General SSHH: Innovation, Implementation and Oral Presentations Thursday, August 28, 2014, 12:45-13:45 h A shortlist of selected abstract authors will present their work during the oral presentation part. Posters Format A0 portrait: 84.1cm x 118.9cm (width x height) Hang-up of the posters: Thursday, August 28, 2014, 09:30-12:00 h The best three SSHH posters will be selected based on poster display on August 28, Posterviewing Posterviewing SSI: Thursday, August 28, 2014, 12:45-13:45 h, Room 3. Posterwalk SSHH: Thursday, August 28, 2014, 14:00-15:30 h, Room 3. The authors are requested to be present at their posters during this time. Awards SSI SSHH SAFE-ID Award 2014 SSI Best papers SSHH Best oral presentations / innovations / implementations* SSHH Best infection control papers SSHH Best posters *Due to very few submission to the innovation / implementation track, these submissions have been integrated with oral presentations and the three prizes will now be awarded for the three best oral presentations / innovations / implementations. Award ceremonies Thursday August 28, 2014 from 17:15 h -17:45 h before the general assemblies of the societies. 7

8 Accommodation For hotel bookings in and near Aarau, please proceed to the website of Aargau Tourism Office: General Social evening The social evening will be held on Thursday, August 28, 2014, 19:30 h at the ancient castle Schloss Lenzburg, 5600 Lenzburg. Costs: Physicians CHF Assistants, nurses, students CHF 50.- You are invited to register online: History of the Castle Lenzburg Castle is one of Switzerland s oldest and most historic hilltop castels. For a thousands years it has played a part in many important events in politics and history across Europe. The early history of Lenzburg Castle belongs to the fog of time. Historians suggest it was originally built as a refuge fort in the Early Middle Ages. The Castellum Lenciburg is first mentionned in connection with Ulrich II, Count of Lenzburg, in a document dated Without any heirs, Ulrich died in 1173 and his estate passed to the Counts of Kyburg. The counts of Kyburg were related through a marriage to the family line of Habsburg-Laufenburg in The Habsburgs built the Knight s Hall and granted Lenzburg as residence and seat of the Habsburg administration. In 1415 the Bernese invaded the former Habsburg territory and from 1444 onwards the Castle served as the residence of the Bernese bailiffs. During the turmoil of the Reformation and the Thirty Years War, the fortifications of Lenzburg Castle were strengthened. The occupation of what is today Canton Aargau by French troops, in 1798, ended the Castle s history as a feudal seat. In 1803 Lenzburg Castle was taken over by the recently formed Canton of Aargau and was used a school for boys until In 1860 the Castle was sold to privat Owners who renovated the Castle as a modern residence. In 1911, an American industrialist acquired the Castle and bequeathed it to his son, Lincoln Ellsworth, a polar explorer, in In 1956 the City of Lenzburg and the Canton of Aargau acquired the Castle, establishing the Lenzburg Castle Foundation. Since then, the Castle and its grounds, including the Knight s Hall, courtyard and garden, have been open to the public. 8

9 Travel information By public transport Aarau is well connected to the Swiss railway and to the international airports in Zurich, Basel and Geneva. From the main train station of Aarau, you may take bus Nr. 1, Nr. 2 or Nr. 4 and get off at Holzmarkt. After a walk of 3 minutes you will arrive at the Congress Centre. By car Aarau can be reached via the A1 motorway from the exits Aarau West (coming from Bern) or Aarau Ost (coming from Zurich). There are no parking possibilites at the Congress Centre. We recommend to take the Kaserne car park which is very close to the venue. General Situation plan Autobahn E60 Ausfahrt Frick/Aarau Kettenbrücke Schlossplatz Mühlemattstrasse Kultur & Kongresshaus Aarau Schlossplatz 9 CH-5000 Aarau Fon: Fax: kuk@aarau.ch Telli Autobahn A1 Ausfahrt Aarau-Ost Kasernen-Parking Rathausgasse Kasernen Parking Gais Schachenalle Bahnhof SBB Hintere Bahnhofstrasse Vordere Vorstadt Schachen Rain Regierungsgebäude Obere Vorstadt Autobahn A1 Ausfahrt Aarau-West 9

10 Partner companies We would like to thank the following companies for supporting the Joint Annual Meeting 2014: General Premium Partner 2014 Partner

11 SCHWEIZERISCHE GESELLSCHAFT FÜR INTENSIVMEDIZIN SOCIÉTÉ SUISSE DE MÉDECINE INTENSIVE SOCIETÀ SVIZZERA DI MEDICINA INTENSIVA SGI-SSMI-SSMI Gemeinsame Jahrestagung 2015 Schweizerische Gesellschaft für Intensivmedizin SGI Schweizerische Gesellschaft für Infektiologie SGInf Schweizerische Gesellschaft für Notfall- und Rettungsmedizin SGNOR Schweizerische Gesellschaft für Spitalhygiene SGSH Réunion annuelle 2015 Société Suisse de Médecine Intensive SSMI Société Suisse d`infectiologie SSinf Société suisse de médecine d urgence et de sauvetage SSMUS Société Suisse d Hygiène Hospitalière SSHH September 2015 Congress Centre Kursaal Interlaken Organized by IMK Institute for medicine and communication Ltd

12 Daily overview Thursday, August 28, 2014 Room 2 Plenary room Room 4 Parallel room Course room 1 Meetings Thursday 08:45-09:15 09:15-09:45 09:45-10:15 10:15-10:30 10:30-10:45 Welcome 14 10:45-11:15 11:15-11:45 11:45-12:15 12:15-12:45 Opening Session Opening Session Video streaming & simultaneous translation Lunch 12:45-13:15 SSHH Session Hepatitis C Session Implementation, Innovation 13:15-13:45 15 and Oral Presentations 14 13:45-14:00 Lunch 14:00-14:30 14:30-15:00 HIV Session SSTTM Workshops 15:00-15:30 15 WS 15:30-16:00 Coffee break 16:00-16:30 16:30-17:00 17:00-17:15 Posterflashes 17:15-17:45 SSI Awards 18 SSHH Awards 18 17:45-18:15 General Assembly General Assembly 18:15-18:45 SSI SSHH from 19:30 16 Social evening 15 Board Meeting SSHH Lunch Together SSI SSHH SSTTM Breaks Meetings (see separate meeting list page 32) WS Workshops 12

13 Course room 2+3 Meetings Room 3 Poster exhibition Room 1 & foyer Industrial exhibition Board Meeting SSI Board Meeting SSTTM General Assembly SSTTM Posters 08:45-09:15 09:15-09:45 09:45-10:15 10:15-10:30 10:30-10:45 10:45-11:15 11:15-11:45 11:45-12:15 12:15-12:45 SSI 12:45-13:15 Lunch Posterviewing 15 13:15-13:45 Posters 13:45-14:00 SSHH Posterwalk Posters 15 14:00-14:30 14:30-15:00 15:00-15:30 Coffee break 15:30-16:00 16:00-16:30 16:30-17:00 17:00-17:15 17:15-17:45 17:45-18:15 18:15-18:45 from 19:30 Thursday 13

14 Scientific program Thursday, August 28, :30-10:45 Room 2 Welcome Ursula Flückiger, Aarau; Bernard Hirschel, Geneva; Matthias Schlegel, St.Gallen; Christoph Hatz, Basel Thursday 10:45-12:15 Room 2 10:45-11:15 11:15-11:45 11:45-12:15 10:45-12:15 Room 4 Opening Session Chair: Bernard Hirschel, Geneva Screening inpatients for resistant pathogens: sense and nonsense Richard Wenzel, Richmond, Virginia (US) Malaria prevention an update Christoph Hatz, Basel Treatment of Hepatitis C the end of interferon Markus Heim, Basel Opening Session: Video streaming & simultaneous translation 12:15-12:45 12:45-13:45 Room 4 Lunch Implementation, Innovation and Oral Presentations Chairs: Christine Mohr-Edokpolo, Aarau; Laurence Senn, Lausanne Elaboration d un guide pratique de prévention et de traitement des infections en établissement médico-social (EMS) C. Petignat, M. Attinger, O. Clerc, F. Beffa, S. Monod; Lausanne GUIDELINES.CH: Mobiler zentraler Hygieneordner C. Kahlert, D. Flury, R. Fulchini, D. Stefanovic, B. Schöbi, G. Rettenmund, M. Schlegel; St.Gallen Adherence to principles of hygiene in operating theatres: development of a monitoring system R. Fulchini, M. Hoffmann, K. De Martin, U. Schaefer, B. Schoebi, M. Schlegel; St.Gallen, Frauenfeld Factors associated with Methicillin-resistance in coagulase-negative staphylococci in deep sternal wound infections after cardiac surgery R. Sommerstein, P. Kohler, M.J. Wilhelm, S.P. Kuster, H. Sax; Zurich Introduction de la désinfection à la vapeur dans la salle d hydrothérapie d un service de grands brûlés M.-J. Thevenin; Lausanne Infectious Risk Moments - a novel, human factors-informed approach to infection prevention L. Clack, J. Schmutz, T. Manser H. Sax; Zurich, Fribourg 14

15 Scientific program Thursday, August 28, :45-13:45 Room 2 12:45-13:15 13:15-13:45 Phase II and Phase III studies in Hepatitis C treatments Chair: Andri Rauch, Bern Directly acting antivirals for the treatment of Hepatitis C: key messages from phase III trials Jean-François Dufour, Bern Eradication of Hepatitis C: myth or reality? Matthew Hickman, Bristol; GB Unrestricted grant: 12:45-13:45 Room 3 Posterviewing SSI 13:45-14:00 14:00-15:30 Room 2 14:00-14:30 14:30-15:00 15:00-15:30 Lunch HIV Session Chairs: Manuel Battegay, Basel; Hansjakob Furrer, Bern Antiviral therapy state of the art now and in the years ahead Joseph Eron, Chape Hill, North Carolina (US) Novel approaches and insights of HIV drug-drug interactions Catia Marzolini, Basel The global scale-up of antiretroviral therapy: epidemiology in action Matthias Egger, Bern Thursday Unrestricted grant: 14:00-15:30 Room 4 14:00-15:30 Room 3 15:30-16:00 SSTTM Workshops Clinical cases from South America, Central Africa and South East Asia Johannes Blum & Andreas Neumayr, Basel Posterwalk SSHH Chairs: Felix Fleisch, Chur; Hugo Sax, Zurich Coffee break 16:00-17:00 Room 2 Posterflashes (details see page 16-17) 15

16 Scientific program Thursday, August 28, 2014 Posterflashes 16:00-17:00 Room 2 16:00-16:05 Posterflashes Nina Khanna Gremmelmaier, Basel; Laurence Senn, Lausanne Clindamycin and Intravenous immunoglobulin influence Group A Streptococcus virulence factor activity A. Tarnutzer, C.M. Zürcher, F. Andreoni, K. Schilcher, R.A. Schüpbach, A.S. Zinkernagel; Zurich Thursday 16:05-16:10 16:10-16:15 Impact of round-the-clock cerebrospinal fluid Gram stain for suspected central nervous system infections on medical therapeutic decisions: does it make a difference? F. Tissot, G. Prod hom, G. Greub; Lausanne Antibiotic use in 61 acute care hospitals in Switzerland: trends over the years and comparison with Europe C. Plüss-Suard, A. Kronenberg, G. Zanetti; Lausanne, Bern 16:15-16:20 16:20-16:25 16:25-16:30 16:30-16:35 16:35-16:40 Heterogeneous quality of Surgical Site Infection (SSI) surveillance in Switzerland M.-C. Eisenring, S.P. Kuster, H. Sax, N. Troillet and Swissnoso; Sion, Zurich Immediate automated detection of nosocomial transmission clusters (HotSpots) D. Flury, M. Hoffmann, Th. Meier, Ph. Kohler, M. Schreiner, M. Schlegel; St.Gallen, Buchs, Zurich Burden of hand soap s contamination by Pseudomonas aeruginosa in a tertiary care hospital: a large molecular epidemiological investigation L. Senn, D.S. Blanc, J.B. Wasserfallen, P. Genoud, G. Prod hom, G. Greub, G. Zanetti; Lausanne Migratory cutaneous lesions in a returning traveler from Australia and Bali case report C.S. Staehelin, M. Bischof, K. Mühlethaler, H.J. Furrer, A. Neumayr; Bern, Köniz, Basel Acute severe kidney injury in HIV-positive patients treated with cart - a case series over 11 years in a cohort of 1153 patients M. Kurz, F. Burkhalter, M. Dickenmann, H. Hopfer, M. Mayr, L. Elzi, M. Battegay; Basel 16

17 Scientific program Thursday, August 28, 2014 Posterflashes 16:40-16:45 16:45-16:50 Hepatitis B: prevalence, risk factors and knowledge of transmission among migrants in prison L. Gétaz, J.M. Gaspoz, H. Wolff; Geneva Hepatitis C virus epidemiology, treatment uptake and outcome in the Swiss HIV Cohort Study, : Where are we now? H. Kovari, B. Ledergerber, M. Cavassini, J. Ambrosioni, A. Bregenzer, M. Stöckle, E. Bernasconi, A. Rauch, R. Weber; Zurich, Lausanne, Geneva, St.Gallen, Basel, Lugano, Bern 16:50-16:55 Protease Inhibitors to Treat Hepatitis C in the Swiss HIV Cohort Study: High Treatment Efficacy but Low Uptake S. Haubitz, V. Schaerer, H. Kovari, B. Ledergerber, J. Ambrosioni, M. Cavassini, M. Stoeckle, P. Schmid, L. Decosterd, H. Guenthard, H. Furrer, K. Metzner, J. Fehr, A. Rauch; Bern, Zurich, Geneva, Lausanne, Basel, St.Gallen Thursday 17

18 Scientific program Thursday, August 28, :15-17:45 Room 2 17:15-17:45 Room 4 SSI Awards SSHH Awards 17:45-18:45 Room 2 General Assembly Swiss Society for Infectious Diseases SSI Thursday 17:45-18:45 Room 4 17:45-18:45 Course room 2+3 General Assembly Swiss Society for Hospital Hygiene SSHH General Assembly Swiss Specialists for Tropical and Travel Medicine FMH SSTTM from 19:30 Social dinner at the ancient castle Schloss Lenzburg 18

19 SATELLITE SYMPOSIUM CONFRONTING CLOSTRIDIUM DIFFICILE INFECTION Friday 29 August 2014, h Hall 2, Kultur & Kongresshaus Aarau Joint Annual Meeting SSI/SSHH/Swiss Society for Tropical and Travel Medicine (FMH) 2014 Chair: Prof. Andreas Widmer, Basel, CH 12:30 12:50 h: CDI epidemiology in Europe (EUCLID study) (Prof. Mark Wilcox, Leeds, UK) 12:50 13:00 h: Clostridium difficile Point Prevalence Study Switzerland (Dr. Sarah Tschudin Sutter, Basel, CH) 13:00 13:20 h: CDI management real life experience (Dr. Duncan Wyncoll, London, UK) 13:20 13:30 h: Discussion Scan the QR code with your smart phone to enter this meeting directly into your calendar. ANTI-INFECTIVES Grindelstrasse 6, CH-8304 Wallisellen APCHDIFIN0614e

20 Daily overview Friday, August 29, 2014 Room 2 Plenary room Room 4 Parallel room Course room 1 Meetings 07:30-08:00 08:00-08:15 08:15-08:30 08:30-09:00 09:00-09:30 Improving antibiotic use Disinfection methods and new approaches 09:30-10:00 10:00-10:30 Coffee break 10:30-11:00 11:00-11:30 11:30-12:00 12:00-12:30 Hepatitis C Session: Difficult to treat patients News in infection control 23 Friday 12:30-13:00 Satellite symposium 13:00-13:30 Astellas Pharma AG 13:30-13:45 13:45-14:15 14:15-14:45 Free communications Symposium Funginos & STCS 14:45-15: :15-15:45 Coffee break 23 Lunch 23 15:45-16:15 Case presentations 16:15-16:45 Diagnostic quiz 16:45 Closing remarks Together SSI SSHH SSTTM Breaks 20

21 Course room 2+3 Meetings Room 3 Poster exhibition Room 1 & foyer Industrial exhibition «Meet the expert» SSTTM Breakfast Session 07:30-08:00 08:00-08:15 08:15-08:30 08:30-09:00 09:00-09:30 09:30-10:00 10:00-10:30 10:30-11:00 11:00-11:30 11:30-12:00 12:00-12:30 Posters Lunch 12:30-13:00 13:00-13:30 13:30-13:45 Friday 13:45-14:15 14:15-14:45 14:45-15:15 15:15-15:45 15:45-16:15 16:15-16:45 16:45 21

22 Scientific program Friday, August 29, :30-08:15 Course room 2+3 «Meet the expert» Breakfast Session SSTTM: Eos where is the worm? Hanspeter Marti, Basel; Robert van der Ploeg, Wetzikon 08:30-10:00 Room 2 08:30-09:00 09:00-09:30 09:30-10:00 Improving antibiotic use Chairs: Christoph A. Fux, Aarau; Pierre-Yves Bochud, Lausanne Fighting new enemies with old weapons: pharmakokinetic insights improve antibiotic performance against multiresistant organisms David Nicolau, Hartford (US) Role of iv-antibiotics Werner Zimmerli, Liestal What s the best antibiotic for the treatment of Staphylococcus aureus? Philippe Moreillon, Lausanne Friday 08:30-10:00 Room 4 08:30-09:00 09:00-09:30 09:30-10:00 Disinfection methods and new approches: sense and/or nonsense Chairs: Marie-Theres Meier, Zurich; Giorgio Zanetti, Lausanne Decontamination of the patient environment overview of (new) methods Markus Dettenkofer, Freiburg (DE) Hydrogen peroxide vapour desinfection Pro Stefan Kuster, Zurich Hydrogen peroxide vapour desinfection Con Benedikt Huttner, Geneva 10:00-10:30 Coffee break 10:30-12:00 Room 2 10:30-11:00 11:00-11:15 11:15-11:45 11:45-12:00 Hepatitis C Session: Difficult to treat patients Chair: Claude Scheidegger, Basel HIV/HCV Coinfection Jürgen Rockstroh, Bonn (DE) Hepatitis C in the Swiss HIV Cohort Study Andri Rauch, Bern Hepatitis C are patients who use drugs (PWUD) really difficult to treat? John Dillon, Dundee (GB) Swiss Data on PWUD Erika Castro, Lausanne Unrestricted grant:

23 Scientific program Friday, August 29, :30-12:00 Room 4 10:30-11:00 11:00-11:30 11:30-12:00 12:00-13:45 News in infection control Chair: Laurence Cuanillon, Clarens; Matthias Schlegel, St.Gallen Revision of the Epidemics Act (EpG): Impact on vaccination, multiresistant strains and health-care associated infections? Daniel Koch, BAG/Bern (v)cjd: Changes in decontamination procedures? Christian Ruef, Zurich Gram-negative multiresistant strains: new Swissnoso infection control guidelines Giorgio Zanetti, Lausanne Lunch 12:30-13:30 Room 2 12:30-12:50 12:50-13:00 13:00-13:20 13:20-13:30 Satellite symposium: Confronting Clostridium Difficile Infection Chair: Andreas Widmer, Basel CDI epidemiology in Europe (EUCLID study) Mark Wilcox, Leeds (GB) Clostridium difficile Point Prevalence Study Switzerland Sarah Tschudin Sutter, Basel CDI management - real life experience Duncan Wyncoll, London (GB) Discussion Friday organized by 13:45-15:15 Room 4 13:45-14:30 14:30-14:50 14:50-15:00 15:00-15:15 Symposium Funginos & Swiss Transplant Cohort Study Chairs: Nicolas Müller, Zurich; Stefan Zimmerli, Bern Fungal diseases: new developments in hematopoietic and solid organ transplantation Olivier Lortholary, Paris (FR) Candidemia in Switzerland: highlights of the 10-year FUNGINOS study Oscar Marchetti, Lausanne Case presentation: A slow-growing infection, a rapid-growing cause, and a never-ending treatment Manuel Oriol, Lausanne Case presentation: Multi-resistant CMV after hematopoietic stem cell transplantation - and now? Nina Khanna Gremmelmaier, Basel 23

24 Scientific program Friday, August 29, :45-15:15 Room 2 15:15-15:45 15:45-16:45 Room 2 Free communications (details see page 25) Coffee break Case presentations - Diagnostic Quiz Chairs: Ursula M. Flückiger, Aarau; Christoph A. Fux, Aarau Diagnostic presentations with different themes 16:45 Room 2 Closing remarks Friday 24

25 Scientific program Friday, August 29, 2014 Free Communications 13:45-15:15 Room 2 13:45-14:00 14:00-14:15 Free Communications Chair: Pierre-Yves Bochud, Lausanne; Helen Kovari, Zurich Rarity of Opportunistic Infections after Solid Organ Transplantation (SOT) in The Swiss Transplant Cohort Study (STCS) C. van Delden, R. Saccilotto, P. Meylan, O. Manuel, C. Garzoni, A. Cusini, H.H. Hirsch, M. Weisser, N. Khanna, K. Boggian, D. Nadal, C. Berger, M. Koller, S. Stampf, N. Mueller, Swiss Transplant Cohort Study; Geneva, Basel, Lausanne, Lugano, Bern, St.Gallen, Zurich Higher Risk of Incident HCV-Coinfections in MSM with a Wide HIV Transmission Bottleneck R.D. Kouyos, A. Rauch, D.L. Braun, W.L. Yang, J. Boni, S. Yerly, T. Klimkait, V. Aubert, C. Shah, H. Kovari, A. Calmy, M. Cavassini, M. Battegay, P.L. Vernazza, E. Bernasconi, B. Ledergerber, H.F. Gunthard; Zurich, Bern, Geneva, Lausanne, Basel, St, Gallen, Lugano 14:15-14:30 The IFNL3/4 G variant increases susceptibility to CMV retinitis among HIV-infected patients S. Bibert, A. Wojtowicz, P. Taffé, O. Manuel, E. Bernasconi, H. Furrer, H.F. Günthard, M. Hoffmann, L. Kaiser, M. Osthoff, M. Cavassini, P.Y. Bochud; Lausanne, Lugano, Bern, Zurich, St.Gallen, Geneva, Basel Friday 14:30-14:45 14:45-15:00 15:00-15:15 The J-curve in HIV: better cardiovascular disease free survival with moderate alcohol intake G. Wandeler, D. Kraus, J. Fehr, A. Conen, A. Calmy, C. Orasch, M. Battegay, P. Schmid, E. Bernasconi, H. Furrer; Bern, Zurich, Aarau, Lausanne, Basel, St.Gallen, Lugano, Geneva Treatment of genital mycoplasma in colonized pregnant women in late pregnancy is associated with a lower rate of premature labour and neonatal complications M. Vouga, G. Greub, G. Prod hom, C. Durussel, M. Roth-Kleiner, S. Vasilevsky, D. Baud; Lausanne Colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae after travelling to South Asia rates, risk factors and beyond E. Kuenzli, V.K. Jaeger, R. Frei, A. Neumayr, S. DeCrom, S. Haller, J. Blum, A.F. Widmer, H. Furrer, M. Battegay, A. Endimiani, C. Hatz; Basel, Zurich, Bern 25

26 NEU Der Wendepunkt in der HCV-Therapie deutliche Verkürzung der Therapie und 90% Heilung bei naiven Patienten mit Genotyp hohe Wirksamkeit über alle Genotypen 1 4 hohe Resistenzbarriere: in Phase III-Studien wurden in Kombination mit PEG + RBV oder nur RBV keine viralen Resistenzen gegen SOVALDI beobachtet* 5 vorteilhaftes Sicherheits- und Verträglichkeitsprofil 5 kurze Therapiedauer: 12 oder 24 Wochen, 1 x tägliche Einnahme 5 * In Kombination mit PEG+RBV oder nur RBV während mindestens 12 Wochen in den Zulassungs studien. 1 Lawitz E, et al. Sofosbuvir for previously un treated chronic hepatitis C infection. N England J Med 2013;368: Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol 2014;30(3): Zeuzem S, et al. Sofosbuvir + Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: the VALENCE trial. AASLD 2013, Washington DC, Poster Lawitz E, et al. Sofosbuvir in Combination With PegIFN and Ribavirin for 12 Weeks Provides High SVR Rates in HCV-Infected Genotype 2 or 3 Treatment Ex perienced Patients with and without Compen sated Cirrhosis: Results from the LONESTAR-2 Study. AASLD 2013, Washington DC, Abstract LB-4. 5 SOVALDI Fachinformation, Stand Januar Gekürzte Fachinformation SOVALDI ZUS: Filmtabletten zu 400 mg Sofosbuvir. IND: SOVALDI wird in Kombination mit anderen Arzneimitteln zur Behandlung der chronischen Hepatitis C bei Erwachsenen angewendet. DOS: Eine Filmtablette täglich zu einer Mahlzeit. Keine Daten zu schwerer Nierenfunktionsstörung, hämodialysepflichtigen Patienten mit end stage renal disease und dekompensierter Leberzirrhose. KI: Überempfindlichkeit gegenüber dem Wirk stoff oder einem der Hilfsstoffe. VM: Nicht zur Anwendung als Monotherapie. Nicht für Kinder und Jugendliche unter 18 Jahren. IA: Nicht gleich zeitig mit P-gp-Induktoren (z.b. Rifampicin und Johhannis kraut) sowie mit Modafinil, Rifa butin, Rifapentin, Carbamazepin, Phenytoin, Pheno barbital, Oxcarbazepin, Telaprevir oder Boce previr anwenden. S/S: Darf nicht in der Schwangerschaft und Stillzeit angewendet werden. UW: Sehr häufig: verminderte Hämo globin konzen tration, Anämie, Neutropenie, Lym pho zyto penie, Thrombozytopenie, Leuko zyto penie, verminder ter Appetit, Schlaflosigkeit, Kopf schmerzen, Schwindel, Dyspnoe, Husten, Diarrhoe, Übelkeit, Erbrechen, erhöhte Bilirubin konzentra tion im Blut, Ausschlag, Pruritus, Arthralgie, Myalgie, Schüttelfrost, grippeähnliche Erkrank ungen, Schmerzen, Fieber, Müdigkeit, Reizbarkeit. Weitere UWs siehe Fachinformation. Abgabekategorie: A. Die vollständige Fach information ist unter publiziert. CH_GS: _201401D Gilead Sciences Switzerland Sàrl Turmstrasse 28, 6300 Zug, HCV/CH/14-03/PI/1197c sto.ch